T-cell prolymphocytic leukemia

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's weight loss doctor NYC
Philadelphia GLP-1 weight loss and GLP-1 clinic NYC

T-cell prolymphocytic leukemia
Prolymphocyte
Synonyms	N/A
Pronounce	N/A
Specialty	N/A
Symptoms	Lymphadenopathy, hepatosplenomegaly, skin rash, fatigue, night sweats, weight loss
Complications	Infection, anemia, thrombocytopenia
Onset	Typically in adulthood
Duration	Chronic
Types	T-cell prolymphocytic leukemia
Causes	Genetic mutations
Risks	Age, genetic predisposition
Diagnosis	Blood test, bone marrow biopsy, immunophenotyping
Differential diagnosis	Chronic lymphocytic leukemia, Sezary syndrome, Adult T-cell leukemia/lymphoma
Prevention	N/A
Treatment	Chemotherapy, immunotherapy, stem cell transplant
Medication	N/A
Prognosis	Generally poor
Frequency	Rare
Deaths	N/A

T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive form of leukemia that affects the T-cells, a type of white blood cell that plays a crucial role in the immune system. This condition is characterized by the proliferation of abnormal T-cells in the blood, bone marrow, and other tissues.

Pathophysiology

T-PLL is caused by genetic mutations that lead to the uncontrolled growth of T-cells. These mutations often involve the T-cell receptor genes and other regulatory genes that control cell growth and apoptosis. The abnormal T-cells in T-PLL are typically larger than normal T-cells and have a distinct appearance under the microscope, known as prolymphocytes.

Clinical Presentation

Patients with T-PLL often present with symptoms such as fatigue, night sweats, and weight loss. Physical examination may reveal lymphadenopathy, hepatosplenomegaly, and skin lesions. Laboratory findings typically show a high white blood cell count with a predominance of abnormal T-cells.

Diagnosis

The diagnosis of T-PLL is based on a combination of clinical findings, laboratory tests, and bone marrow biopsy. Flow cytometry is used to identify the specific immunophenotype of the T-cells, which is crucial for distinguishing T-PLL from other types of leukemia. Cytogenetic analysis may reveal characteristic chromosomal abnormalities.

Treatment

Treatment options for T-PLL are limited and often involve chemotherapy and immunotherapy. The monoclonal antibody alemtuzumab is commonly used in the treatment of T-PLL. In some cases, hematopoietic stem cell transplantation may be considered, especially in younger patients.

Prognosis

The prognosis for T-PLL is generally poor, with a median survival of less than two years. The aggressive nature of the disease and its resistance to conventional therapies contribute to the poor outcome.

See also

• Leukemia
• T lymphocyte
• Hematopoietic stem cell transplantation